- Home
- OSCR vs CORT Comparison
OSCR vs CORT Comparison
Compare OSCR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSCR | CORT |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 9.7B |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | OSCR | CORT |
|---|---|---|
| Price | $29.93 | $114.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $16.88 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 4.9M | 839.3K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.16 | 0.09 |
| Revenue | ★ $11,701,427,000.00 | $761,407,000.00 |
| Revenue This Year | $63.89 | $26.08 |
| Revenue Next Year | $5.30 | $26.98 |
| P/E Ratio | ★ $9.14 | $1,310.33 |
| Revenue Growth | ★ 27.50 | 12.79 |
| 52 Week Low | $10.69 | $28.66 |
| 52 Week High | $34.48 | $126.38 |
Technical Indicators
Market Signals| Indicator | OSCR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 53.00 |
| Support Level | $28.13 | $108.33 |
| Resistance Level | $33.08 | $124.30 |
| Average True Range (ATR) | 1.93 | 5.73 |
| MACD | -0.40 | -0.08 |
| Stochastic Oscillator | 24.35 | 58.65 |
Price Performance
Historical ComparisonAbout OSCR Oscar Health Inc.
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.